January 12, 2021 Uncategorized

BD Provides Updates To Its Fiscal 2021 Financial Outlook And Intends To Comment On Its Preliminary First Fiscal Quarter Revenue Performance During Today's Webcast At The 39th Annual J.P. Morgan Healthcare Conference

FRANKLIN LAKES, N.J., Jan. 12, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31, 2020.   “We have entered fiscal 2021 with strong momentum and now expect to deliver fiscal 2021 revenues toward the high-end of... Read more

January 12, 2021 Uncategorized

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer

Basel, 12 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Read more

January 11, 2021 Environ, Ag./Food & Bev Product Launch

New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is transforming genomic data bottlenecks into catalysts with the launch of Illumina Connected Analytics (ICA). This new and integrated bioinformatics solution provides a comprehensive, private, cloud-based data platform that empowers customers to manage, analyze, and explore large volumes of multi-omic data in a secure, scalable, and flexible environment. “Illumina... Read more

January 11, 2021 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 Licensing, IP, and Legal M&A, Partnerships Product Launch

Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling

SAN DIEGO–(BUSINESS WIRE)–With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s commitment to develop standardized, globally distributable tools for precision oncology. Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina... Read more

January 11, 2021 PR/Corporate

Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full financial results for the fourth quarter and the fiscal year... Read more

January 11, 2021 PR/Corporate

Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full financial results for the fourth quarter and the fiscal year... Read more

January 11, 2021 PR/Corporate

Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full financial results for the fourth quarter and the fiscal year... Read more

January 11, 2021 Product Launch

Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer

Basel, 11 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support... Read more

January 11, 2021 Product Launch

Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years

Basel, 11 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above. In addition, the EC has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above.... Read more